Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oxford University

- PMLiVE

CHMP rejects Kyowa Kirin’s Parkinson’s disease drug

Results of eight main studies of drug were 'inconsistent', according to the CHMP

Bayer symbol

Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy

In 2019, Bayer bought out its private equity partner Versant Ventures and founders in BlueRock Therapeutics for $240m

- PMLiVE

Anavex’s CNS drug slows progression of motor and non-motor symptoms in Parkinson’s disease

Clinical benefit correlated with increase in target biomarker SIGMAR1

- PMLiVE

Oxford University to study antiparasitic drug ivermectin in COVID-19 trial

The potential COVID-19 treatment will be investigated as part of the large-scale PRINCIPLE trial

- PMLiVE

Servier, Oncodesign select first preclinical candidate from Parkinson’s disease collaboration

Oncodesign received the first milestone payment in February 2020 as part of the collaboration

- PMLiVE

Annovis Bio’s lead therapeutic shows ‘significant improvements’ in Alzheimer’s, Parkinson’s

Patients from a small phase 2a study saw their ADAS-Cog11 scores improve by 4.4 points

- PMLiVE

Prothena achieves $60m milestone as part of Roche collaboration

Milestone reached as first patient doses in phase 2b trial of prasinezumab in early Parkinson's disease patients

dengue fever mosquito

Oxford University’s malaria vaccine is 77% effective

First vaccine to meet WHO-specified efficacy goal of 75%, says research team

- PMLiVE

Single dose of COVID-19 vaccines ‘significantly’ reduces infections

Infections fell by 65% after first dose of AZ/Oxford or Pfizer/BioNTech vaccines

- PMLiVE

Oxford University, Prenetics to advance COVID-19 rapid testing for other infectious diseases

Rapid testing technology at the core of the collaboration is used in Oxford University's COVID-19 test

- PMLiVE

Oxford study finds standard asthma medication improves recovery time in COVID-19 patients

Early treatment with inhaled budesonide could help high-risk patients

- PMLiVE

New restrictions for AZ/Oxford COVID-19 vaccine despite EMA endorsement

Regulators in Canada and Germany have reportedly placed new restrictions on vaccine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links